atopica logo

ATOPICA® (cyclosporine capsules) USP MODIFIED

Captar Logo

Capstar® (nitenpyram)

Clomicalm Logo 4C 2016

Clomicalm® (clomipramine hydrochloride)

Percorten-V Logo

Percorten®-V (desoxycorticosterone pivalate injectable suspension)

Surolan Logo

Surolan® (miconazole nitrate, polymyxin B sulfate, prednisolone acetate)

Zobuxa logo

Zobuxa® (enrofloxacin)

Percorten-V Logo
Percorten®-V (desoxycorticosterone pivalate injectable suspension)

A proven history of life-saving results

Canine Addison’s disease (hypoadrenocorticism) is characterized by inadequate production of glucocorticoids (cortisol) and/or mineralocorticoids (aldosterone) by the adrenal glands. If left untreated, the disease is life-threatening.

As the first FDA-approved treatment for canine Addison’s disease* Percorten-V continues to be a trusted solution that gives hope to pet owners in the face of this challenging diagnosis.

Click here to learn more.

*For use as a replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.

Important Safety Information

Do not use in pregnant dogs or in dogs suffering from congestive heart failure, severe renal disease, or edema. Reduce dosage in dogs showing signs of hypernatremia or hypokalemia. Like other adrenocortical hormones, Percorten-V may cause severe side effects if dosage is too high or prolonged. The most common adverse reactions reported were depression/lethargy, vomiting, anorexia, polydipsia, and polyuria. Some of these effects may resolve with adjustments in dose or interval of Percorten-V or concomitant glucocorticoid administration. Please see product insert for full prescribing information.

Percorten is a trademark of Eli Lilly and Company or its affiliates.